Trial Profile
Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Everolimus (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 02 Dec 2015 New trial record